Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2025, titled "Zydus receives final approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg".
Press Release Mar 16 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 14 2025
- Press Release Mar 12 2025
- Press Release Mar 10 2025
- Press Release Mar 05 2025
- Press Release Mar 04 2025
Later from Zydus Lifesciences
- Press Release Mar 18 2025
- Press Release Apr 11 2025
- Press Release Apr 16 2025
- Press Release Apr 17 2025
- ITC Reversal Of Common ITC U/s17(2) Required In Relation To Activity Of Subscription And Redemption Of Mutual Funds
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences